Oscillatory relaxation of zonal flows in a multi-species stellarator plasma

The low frequency oscillatory relaxation of zonal potential perturbations is studied numerically in the TJ-II stellarator (where it was experimentally detected for the first time). It is studied in full global gyrokinetic simulations of multi-species plasmas. The oscillation frequency obtained is compared with predictions based on single-species simulations using simplified analytical relations. It is shown that the frequency of this oscillation for a multi-species plasma can be accurately obtained from single-species calculations using extrapolation formulas. The damping of the oscillation and the influence of the different inter-species collisions is studied in detail. It is concluded that taking into account multiple kinetic ions and electrons with impurity concentrations realistic for TJ-II plasmas allows to account for the values of frequency and damping rate in zonal flows relaxations observed experimentally.Comment: 11 figures, 22 page

Caracterización Proteómica in vivo de células endoteliales circulantes y células progenitoras de endoteliales an pacientes con síndrome coronario agudo

Comunicaciones a congreso

The influence of wildfires on aerosol size distributions in rural areas

The number of particles and their size distributions were measured in a rural area, during the summer, using a PCASP-X. The aim was to study the influence of wildfires on particle size distributions. The comparative studies carried out reveal an average increase of around ten times in the number of particles in the fine mode, especially in sizes between 0.10 and 0.14 μm, where the increase is of nearly 20 times. An analysis carried out at three different points in time--before, during, and after the passing of the smoke plume from the wildfires--shows that the mean geometric diameter of the fine mode in the measurements affected by the fire is smaller than the one obtained in the measurements carried out immediately before and after (0.14 μm) and presents average values of 0.11 μm.publishe

Ionic and electronic structure of sodium clusters up to N=59

We determined the ionic and electronic structure of sodium clusters with even electron numbers and 2 to 59 atoms in axially averaged and three-dimensional density functional calculations. A local, phenomenological pseudopotential that reproduces important bulk and atomic properties and facilitates structure calculations has been developed. Photoabsorption spectra have been calculated for $\mathrm{Na}_2$, $\mathrm{Na}_8$, and $\mathrm{Na}_9^+$ to $\mathrm{Na}_{59}^+$. The consistent inclusion of ionic structure considerably improves agreement with experiment. An icosahedral growth pattern is observed for $\mathrm{Na}_{19}^+$ to $\mathrm{Na}_{59}^+$. This finding is supported by photoabsorption data.Comment: To appear in Phys. Rev. B 62. Version with figures in better quality can be requested from the author

A semantic interoperability approach to support integration of gene expression and clinical data in breast cancer

The introduction of omics data and advances in technologies involved in clinical treatment has led to a broad range of approaches to represent clinical information. Within this context, patient stratification across health institutions due to omic profiling presents a complex scenario to carry out multi-center clinical trials.This paper presents a standards-based approach to ensure semantic integration required to facilitate the analysis of clinico-genomic clinical trials. To ensure interoperability across different institutions, we have developed a Semantic Interoperability Layer (SIL) to facilitate homogeneous access to clinical and genetic information, based on different well-established biomedical standards and following International Health (IHE) recommendations.The SIL has shown suitability for integrating biomedical knowledge and technologies to match the latest clinical advances in healthcare and the use of genomic information. This genomic data integration in the SIL has been tested with a diagnostic classifier tool that takes advantage of harmonized multi-center clinico-genomic data for training statistical predictive models.The SIL has been adopted in national and international research initiatives, such as the EURECA-EU research project and the CIMED collaborative Spanish project, where the proposed solution has been applied and evaluated by clinical experts focused on clinico-genomic studies

Biomedical point-of-care microanalyzer for potentiometric determination of ammonium ion in plasma and whole blood

Acord transformatiu CRUE-CSICSome inborn errors of metabolism and other diseases can result in increasing blood ammonium (hyperammonemia episodes), which can cause serious neurological complications in patients or even death. Early diagnosis, follow up and treatment are essential to minimize irreversible damages in brain. Currently, adequate analytical instrumentation for the necessary ammonium bedside determination is not available in all health centers but only in clinical laboratories of reference hospitals. We therefore have developed a low cost and portable potentiometric Point-of-Care microanalyzer (POC) to address this problem. It consists of a cyclic olefin copolymer-based microanalyzer, the size of a credit card and working in continuous flow, which integrates microfluidics, a gas-diffusion module and a potentiometric detection system. The analytical features achieved are a linear range from 30 to 1000 μmol L NH , a detection limit of 18 μmol L NH and a required sample volume of 100 μL, which comply with the medical requirements. Plasma and blood samples are analyzed with no significant differences observed between ammonium concentrations obtained with both the proposed microanalyzer and the reference method. This demonstrates the value of the developed POC for bedside clinical applications

Testing of a novel automated point-of-care analyzer for blood ammonium monitoring in a clinical setting

Altres ajuts: acords transformatius de la UABCertain diseases are marked by elevated ammonium levels in the blood, a condition known as hyperammonemia. Prompt detection and medical intervention are crucial to prevent potentially fatal outcomes. Therefore, ammonium levels should be monitored regularly, typically in referral hospitals where specialized and costly equipment is available. Although compact commercial devices are available for this purpose, none of them meet all the technical and analytical requirements needed for direct blood analysis, and current reported strategies have not been validated with enough samples to confirm results reliably. We present a robust and reliable automated point-of-care (POC) analyzer for the potentiometric determination of ammonium in blood. Comprising three computer-controlled modules-fluid management, detection, and data acquisition and transmission-this system combines portability, ease of use, and affordability. It can directly measure untreated blood samples, significantly reducing analysis time. Fully automated, it operates unsupervised with minimal lab personnel intervention. Analytical quality parameters include 5% RSD repeatability (n = 8), a limit of detection of 24 μM, a working range of 30-1000 µM and a sample volume of 215 µL. Successfully implemented in a hospital for 2 months, it analyzed 238 blood samples in parallel with the hospital's reference method showing comparable results (paired t-test, Passing-Bablok regression and Bland-Altman Plot) and randomly distributed errors, with a 4% accuracy calculated as mean error. Results indicate the POC analyzer effectiveness and reliability in a clinical setting compared to currently reported or commercially available equipment, being suitable for bedside monitoring of conditions associated with hyperammonemia in healthcare centers, including emergency rooms and clinics in developing countries

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF

M. Kaste on työryhmän ROCKET AF Steering Comm jäsen.Background-Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. Methods and Results-In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intention-to-treat population. The median age was 73 years, and the mean CHADS(2) score was 3.5. Over 1.9 years of median follow-up, 1214 (8.6%) patients died. Kaplan-Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33-1.70, P= 75 years (hazard ratio 1.69, 95% CI 1.51-1.90, P Conclusions-In a large population of patients anticoagulated for nonvalvular atrial fibrillation, approximate to 7 in 10 deaths were cardiovascular, whereasPeer reviewe

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)